These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2693621)

  • 61. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF).
    Toffoli G; Veronesi A; Boiocchi M; Crivellari D
    Ann Oncol; 2000 Mar; 11(3):373-4. PubMed ID: 10811509
    [No Abstract]   [Full Text] [Related]  

  • 63. Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery.
    Faul C; Brufsky A; Gerszten K; Flickinger J; Kunschner A; Jacob H; Vogel V
    Eur J Cancer; 2003 Apr; 39(6):763-8. PubMed ID: 12651201
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
    Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Methylprednisolone and chlorpromazine in patients receiving cancer chemotherapy: a prospective non-randomized study.
    Gez E; Brufman G; Kaufman B; Yitzhaki N; Gera C; Ben-Baruch N; Sulkes A; Biran S
    J Chemother; 1989 Apr; 1(2):140-3. PubMed ID: 2732782
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial.
    Joss RA; Galeazzi RL; Bischoff AK; Pirovino M; Ryssel HJ; Brunner KW
    Clin Pharmacol Ther; 1986 Jun; 39(6):619-24. PubMed ID: 3519041
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience.
    Leone JP; Leone J; Vallejo CT; Pérez JE; Romero AO; Machiavelli MR; Romero Acuña L; Domínguez ME; Langui M; Fasce HM; Leone BA; Ortiz E; Iturbe J; Zwenger AO
    Breast Cancer Res Treat; 2014 Jan; 143(2):313-23. PubMed ID: 24327333
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
    Tormey DC; Weinberg VE; Holland JF; Weiss RB; Glidewell OJ; Perloff M; Falkson G; Falkson HC; Henry PH; Leone LA
    J Clin Oncol; 1983 Feb; 1(2):138-45. PubMed ID: 6366133
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of antiemetic activity of chloropromazine and high doses of metoclopramide in cisplatin-based chemotherapy.
    Tsavaris NB; Papaioannou D; Beldecos D; Kakoliris S; Mylonakis N; Karvounis N; Komitsopoulou P; Karagiaouris P; Sarmas J; Tzannou I
    Acta Oncol; 1990; 29(8):1005-9. PubMed ID: 2278720
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Antiemetic activity of high-dose methylprednisolone associated with continuous-infusion metoclopramide and oral alprazolam during multiple-day chemotherapy.
    Salles G; Archimbaud E; Thomas X; Fiere D
    Cancer Chemother Pharmacol; 1991; 28(1):77-9. PubMed ID: 2040038
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
    Roila F; Tonato M; Basurto C; Bella M; Passalacqua R; Morsia D; DiCostanzo F; Donati D; Ballatori E; Tognoni G
    J Clin Oncol; 1987 Jan; 5(1):141-9. PubMed ID: 3543234
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroid, in malignant lymphoma patients receiving non-cisplatin chemotherapy.
    Jørgensen M; Victor MA
    Acta Oncol; 1996; 35(2):159-63. PubMed ID: 8639310
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
    Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
    Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial.
    Semiglasov VF; Stepula VV; Dudov A; Lehmacher W; Mengs U
    Anticancer Res; 2004; 24(2C):1293-302. PubMed ID: 15154663
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis.
    Grunberg SM; Akerley WL; Krailo MD; Johnson KB; Baker CR; Cariffe PA
    Cancer Invest; 1986; 4(5):379-85. PubMed ID: 3801953
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
    Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
    Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Paul NA; Zee B; Fine S; Pater J
    J Clin Oncol; 1996 Oct; 14(10):2731-7. PubMed ID: 8874334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.